The Food and Drug Administration yesterday approved a new pre-exposure prophylaxis (PrEP) for certain adults and adolescents who do not have HIV but are at risk for infection from sex. The drug, Descovy, previously was approved for use with other antiretoviral drugs to treat HIV infection in adults and pediatric patients. “PrEP drugs are highly effective when taken as indicated in the drug labeling and can prevent HIV infection,” said Jeffrey Murray, M.D., deputy director for the division of antiviral products at FDA’s Center for Drug Evaluation and Research. “This approval provides more prevention options for certain patients at-risk for acquiring HIV.”

Related News Articles

Headline
The Food and Drug Administration May 16 announced it cleared the first blood test to diagnose Alzheimer’s disease. The test, created by Fujirebio Diagnostics,…
Headline
The National Institutes of Health May 8 released an analysis that found incidences of 14 types of cancer increased among people under age 50 from 2010-2019.…
Headline
A New England Journal of Medicine study published yesterday found success in administering dostarlimab, an immunotherapy drug, to a group of 103 cancer…
Headline
Overall cancer death rates declined steadily among both men and women from 2018 through 2022, according to the National Institutes of Health's latest annual…
Headline
A study published April 14 by JAMA Network Open found that rates of pancreatic and colon cancer rose among young adults from 2000-2021. Researchers examined…
Headline
The Centers for Medicare & Medicaid Services April 10 released key priorities for new CMS Administrator Mehmet Oz, who was confirmed to the position April…